• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Zenas BioPharma, Inc. - Common Stock (NQ:ZBIO)

    27.76 +1.86 (+7.18%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 9, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 834,820
    Open 26.21
    Bid (Size) 28.40 (10)
    Ask (Size) 28.70 (1)
    Prev. Close 25.90
    Today's Range 25.51 - 28.72
    52wk Range 5.830 - 26.59
    Shares Outstanding 41,793,412
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Zenas Biopharma Raises $120 Million To Secure Global Rights To Multiple Sclerosis Drug
    Zenas BioPharma secures global rights to orelabrutinib in multiple sclerosis, expands autoimmune pipeline, and raises $120 million in private placement. 
    Via Benzinga
    Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis
    From Zenas BioPharma
    Via GlobeNewswire

    Performance

    YTD
    +208.1%
    +208.1%
    1 Month
    +29.0%
    +29.0%
    3 Month
    +164.6%
    +164.6%
    6 Month
    +270.6%
    +270.6%
    1 Year
    +56.9%
    +56.9%

    More News

    Read More
    Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million
    From Zenas BioPharma
    Via GlobeNewswire
    Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences
    From Zenas BioPharma
    Via GlobeNewswire
    Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
    From Zenas BioPharma
    Via GlobeNewswire
    Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Zenas BioPharma
    Via GlobeNewswire
    ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma
    From Faruqi & Faruqi, LLP
    Via Business Wire
    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO
    From Pomerantz LLP
    Via GlobeNewswire
    SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    ZBIO DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel Before Important June 16 Deadline in Securities Class Action First Filed by the Firm – ZBIO
    From The Rosen Law Firm PA
    Via GlobeNewswire
    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO
    From Pomerantz LLP
    Via GlobeNewswire
    Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ibotta, NET Power, Zenas BioPharma, and Avis Budget and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO
    From Pomerantz LLP
    Via GlobeNewswire
    Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ibotta, NET Power, Zenas BioPharma, and BigBear and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO
    From Pomerantz LLP
    Via GlobeNewswire
    ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ZBIO
    From The Rosen Law Firm PA
    Via GlobeNewswire
    ROSEN, THE FIRST FILING FIRM, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ZBIO
    From The Rosen Law Firm PA
    Via GlobeNewswire
    Zenas BioPharma to Present at the Jefferies Global Healthcare Conference
    From Zenas BioPharma
    Via GlobeNewswire
    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO
    From Pomerantz LLP
    Via GlobeNewswire
    ROSEN, A LEADING LAW FIRM, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ZBIO
    From The Rosen Law Firm PA
    Via GlobeNewswire
    ROSEN, THE FIRST FILING FIRM, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ZBIO
    From The Rosen Law Firm PA
    Via GlobeNewswire
    ZBIO Investors Have the Opportunity to Lead the Zenas BioPharma Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO
    From Pomerantz LLP
    Via GlobeNewswire

    Frequently Asked Questions

    Is Zenas BioPharma, Inc. - Common Stock publicly traded?
    Yes, Zenas BioPharma, Inc. - Common Stock is publicly traded.
    What exchange does Zenas BioPharma, Inc. - Common Stock trade on?
    Zenas BioPharma, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Zenas BioPharma, Inc. - Common Stock?
    The ticker symbol for Zenas BioPharma, Inc. - Common Stock is ZBIO on the Nasdaq Stock Market
    What is the current price of Zenas BioPharma, Inc. - Common Stock?
    The current price of Zenas BioPharma, Inc. - Common Stock is 27.76
    When was Zenas BioPharma, Inc. - Common Stock last traded?
    The last trade of Zenas BioPharma, Inc. - Common Stock was at 10/09/25 04:00 PM ET
    What is the market capitalization of Zenas BioPharma, Inc. - Common Stock?
    The market capitalization of Zenas BioPharma, Inc. - Common Stock is 1.16B
    How many shares of Zenas BioPharma, Inc. - Common Stock are outstanding?
    Zenas BioPharma, Inc. - Common Stock has 1B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.